{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-Cell+Non+Hodgkin+Lymphoma&page=59", "query": { "condition": "B-Cell Non Hodgkin Lymphoma", "page": 59 }, "page_size": 10 }, "pagination": { "page": 59, "page_size": 10, "total_count": 2217, "total_pages": 222, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-Cell+Non+Hodgkin+Lymphoma&page=60&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-Cell+Non+Hodgkin+Lymphoma&page=58&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T10:35:30.195Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00655837", "title": "Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "SGN-40", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2008-04", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2014-12-18", "last_synced_at": "2026-10-20T10:35:30.195Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Aurora, Colorado + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Park Ridge", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00655837" }, { "nct_id": "NCT04981795", "title": "realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "Tafasitamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2021-09-20", "completion_date": "2026-01-23", "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-10-20T10:35:30.195Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Orange, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "Ames", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04981795" }, { "nct_id": "NCT03533283", "title": "An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkins Lymphoma" ], "interventions": [ { "name": "Glofitamab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "89Zr-Df-IAB22M2C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 211, "start_date": "2018-05-08", "completion_date": "2026-10-16", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-20T10:35:30.195Z", "location_count": 1, "location_summary": "Charlotte, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03533283" }, { "nct_id": "NCT05255354", "title": "Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Follicular Lymphoma", "Diffuse Large B Cell Lymphoma", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "ClonoSEQ", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Adaptive Biotechnologies", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2022-06-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2024-08-22", "last_synced_at": "2026-10-20T10:35:30.195Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05255354" }, { "nct_id": "NCT00278161", "title": "Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 94, "start_date": "2005-01", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2018-11-05", "last_synced_at": "2026-10-20T10:35:30.195Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00278161" }, { "nct_id": "NCT00614042", "title": "Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)", "Non-Hodgkin's Lymphoma (NHL)" ], "interventions": [ { "name": "TRU-016 (anti-CD37 protein therapeutic)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aptevo Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2008-01", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2017-06-28", "last_synced_at": "2026-10-20T10:35:30.195Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Augusta, Georgia • Boston, Massachusetts + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00614042" }, { "nct_id": "NCT00003805", "title": "Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bone Marrow Suppression", "Fever, Sweats, and Hot Flashes", "Infection", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Unspecified Adult Solid Tumor, Protocol Specific", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "piperacillin sodium", "type": "DRUG" }, { "name": "piperacillin-tazobactam", "type": "DRUG" }, { "name": "tazobactam sodium", "type": "DRUG" }, { "name": "vancomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "European Organisation for Research and Treatment of Cancer - EORTC", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 859, "start_date": "1997-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-09-24", "last_synced_at": "2026-10-20T10:35:30.195Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Boston, Massachusetts", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003805" }, { "nct_id": "NCT01599559", "title": "Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Primary Mediastinal B-cell Lymphoma" ], "interventions": [ { "name": "observation", "type": "OTHER" }, { "name": "3D-Conformal Radiotherapy (3D-CRT)", "type": "RADIATION" } ], "intervention_types": [ "OTHER", "RADIATION" ], "sponsor": "International Extranodal Lymphoma Study Group (IELSG)", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 540, "start_date": "2012-10", "completion_date": "2029-12-17", "has_results": false, "last_update_posted_date": "2026-01-15", "last_synced_at": "2026-10-20T10:35:30.195Z", "location_count": 3, "location_summary": "Louisville, Kentucky • Rochester, Minnesota • Houston, Texas", "locations": [ { "city": "Louisville", "state": "Kentucky" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01599559" }, { "nct_id": "NCT01321541", "title": "Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-cell Lymphoma", "de Novo DLBCL", "DLBCL Transformed From Indolent Lymphoma", "Follicular Grade 3 Lymphoma" ], "interventions": [ { "name": "Pixantrone + Rituximab", "type": "DRUG" }, { "name": "Gemcitabine + Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CTI BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 312, "start_date": "2011-04-20", "completion_date": "2018-09-14", "has_results": true, "last_update_posted_date": "2021-11-19", "last_synced_at": "2026-10-20T10:35:30.195Z", "location_count": 51, "location_summary": "Tucson, Arizona • Bentonville, Arkansas • Fayetteville, Arkansas + 39 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Bentonville", "state": "Arkansas" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01321541" }, { "nct_id": "NCT05400122", "title": "Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Hematologic Malignancy", "Rectum Cancer", "Acute Myeloid Leukemia", "Myelodysplastic Syndromes", "Acute Lymphoblastic Leukemia", "Chronic Myeloid Leukemia", "Chronic Lymphocytic Leukemia", "Hodgkin Lymphoma", "Non Hodgkin Lymphoma", "Myeloproliferative Syndrome", "Plasma Cell Myeloma", "Gastric Cancer", "Esophageal Cancer", "Esophagus Cancer", "Gastric Cancer, Metastatic", "Unresectable Esophageal Cancer", "Metastatic Esophageal Cancer" ], "interventions": [ { "name": "Vactosertib", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" }, { "name": "Natural Killer Cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Wald", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2022-09-09", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-10-20T10:35:30.195Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05400122" } ] }